InventisBio (SH:688382) Zheng Quan Ri Bao Wang·2025-04-27 11:15Core Insights - Yifang Biotechnology (Shanghai) Co., Ltd. reported a revenue of 169 million yuan for 2024, a year-on-year decrease of 9.02%, and a net loss of 240 million yuan, which is a 15.41% reduction in losses compared to the previous year [1] - The company has made significant progress in its innovative drug development pipeline, although it has not yet achieved profitability [1][2] - The decline in revenue is primarily attributed to reduced income from technology licensing and the lack of substantial sales from new products [1] Financial Performance - Total revenue for 2024 was 169 million yuan, down 9.02% year-on-year [1] - Net loss for the year was 240 million yuan, with a year-on-year improvement of 15.41% [1] - Cumulative unabsorbed losses reached 2.545 billion yuan [1] Product Development - Yifang Biotechnology has received approval for two products: Beifutine (brand name: Saimeina) and Gexuolei (brand name: Anfangning) [1] - The company is advancing its pipeline with several key products, including D-2570 (a TYK2 inhibitor) for moderate to severe psoriasis, which has shown significant efficacy in clinical trials [2] - Other products in development include D-0502 (an oral SERD for breast cancer) and D-0120 (a URAT1 inhibitor), both of which are progressing through clinical trials [2] Commercialization Strategy - The company relies on technology licensing and product sharing for revenue generation [1] - Yifang Biotechnology plans to leverage partner channels for commercialization while exploring its own sales model to accelerate product value realization [2] - The sales team has not yet been established for products outside of licensed offerings, indicating a need for further development in this area [2]